Financial Tear Sheet
Millendo Therapeutics is a late-stage biopharmaceutical company focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. The Company’s objective is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. The Company is currently advancing livoletide for the treatment of Prader-Willi syndrome and nevanimibe for the treatment of classic congenital adrenal hyperplasia and endogenous Cushing’s syndrome.
|Intraday High||52 Week High|
|Intraday Low||52 Week Low|
|Today's Open||Currency||US Dollar|
Copyright West LLC. Minimum 15 minutes delayed.
Primary IR Contact
|06/06/2019 11:00 AM EDT||
|05/22/2019 10:00 AM EDT||